| 3 mg/kg QW n = 1 | 10 mg/kg QW n = 5 | 20 mg/kg QW n = 6 | 40 mg/kg QW RDE, n = 36 | 20 mg/kg Q2W n = 6 | All patients N = 54 |
---|---|---|---|---|---|---|
Age, years | Â | |||||
 Median (range) | 57.0 (57.0–57.0) | 55.0 (48.0–66.0) | 56.5 (43.0–69.0) | 60.5 (36.0–77.0) | 54.5 (49.0–78.0) | 58.0 (36.0–78.0) |
 <65 years, n (%) | 1 (100) | 3 (60) | 5 (83) | 24 (67) | 5 (83) | 38 (70) |
 ≥65 years, n (%) | 0 | 2 (40) | 1 (17) | 12 (33) | 1 (17) | 16 (30) |
Sex, n (%) | Â | |||||
 Female | 0 | 2 (40) | 2 (33) | 11 (31) | 2 (33) | 17 (31) |
 Male | 1 (100) | 3 (60) | 4 (67) | 25 (69) | 4 (67) | 37 (69) |
Race, n (%) | Â | |||||
 Asian | 0 | 0 | 0 | 17 (47) | 0 | 17 (31) |
 Black | 0 | 0 | 0 | 1 (3) | 0 | 1 (2) |
 Caucasian | 1 (100) | 5 (100) | 6 (100) | 18 (50) | 5 (83) | 35 (65) |
 Other | 0 | 0 | 0 | 0 | 1 (17) | 1 (2) |
ECOG PS, n (%) | Â | |||||
 0 | 0 | 1 (20) | 1 (17) | 7 (19) | 2 (33) | 11 (20) |
 1 | 1 (100) | 4 (80) | 5 (83) | 26 (72) | 4 (67) | 40 (74) |
 2 | 0 | 0 | 0 | 3 (8) | 0 | 3 (6) |
Initial diagnosis, n (%) | Â | |||||
 Head and neck | 1 (100) | 4 (80) | 2 (33) | 12 (33) | 2 (33) | 21 (39) |
 Esophageal | 0 | 0 | 1 (17) | 12 (33) | 2 (33) | 15 (28) |
 Breast | 0 | 1 (20) | 2 (33) | 5 (14) | 2 (33) | 10 (19) |
 Gastric | 0 | 0 | 1 (17) | 7 (19) | 0 | 8 (15) |
Primary tumor histology, n (%) | Â | |||||
 Squamous cell carcinoma | 1 (100) | 4 (80) | 2 (33) | 22 (61) | 2 (33) | 31 (57) |
 Other | 0 | 1 (20) | 4 (67) | 14 (39) | 4 (67) | 23 (43) |
Stage at study entry, n (%) | Â | |||||
 III–IIIC | 0 | 1 (20) | 0 | 4 (11) | 0 | 5 (9) |
 IV–IVB | 1 (100) | 4 (80) | 6 (100) | 32 (89) | 6 (100) | 49 (91) |
Prior antineoplastic regimen(s), n (%) | Â | |||||
 No | 0 | 0 | 0 | 1 (3) | 0 | 1 (2) |
 Yes | 1 (100) | 5 (100) | 6 (100) | 35 (97) | 6 (100) | 53 (98) |
Prior EGFR or HER2-directed therapy, n (%) | Â | |||||
 Cetuximab | 1 (100) | 3 (60) | 2 (33) | 8 (22) | 2 (33) | 16 (30) |
 Pertuzumab | 0 | 0 | 0 | 1 (3) | 0 | 1 (2) |
 Trastuzumab | 0 | 1 (20) | 4 (67) | 11 (31) | 2 (33) | 18 (33) |
 Trastuzumab emtansine | 0 | 1 (20) | 0 | 1 (3) | 1 (17) | 3 (6) |
 Number of prior regimens, median (range) | 5.0 (5.0–5.0) | 4.0 (2.0–7.0) | 2.5 (2.0–5.0) | 3.0 (1.0–12.0) | 3.0 (1.0–4.0) | 3.0 (1.0–12.0) |